Filana Therapeutics
FLNA
44 hedge funds and large institutions have $57.9M invested in Filana Therapeutics in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 5 closing their positions.
29% more capital invested
Capital invested by funds: $44.8M → $57.9M (+$13.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
10% less funds holding
Funds holding: 49 → 44 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.15M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$550K |
| 3 |
Renaissance Technologies
New York
|
+$100K |
| 4 |
6CM
683 Capital Management
New York
|
+$46.2K |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$36.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$789K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$90K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$82.4K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$63K |
| 5 |
Goldman Sachs
New York
|
-$51K |
FLNA Hedge Fund Activity: Q1 2016 in Review
44 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2016, worth a combined $57.9M — up 29% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FLNA and 0 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was Nantahala Capital Management, adding an estimated $1.15M. The largest seller was J. Goldman & Co, cutting an estimated $789K.
- 44 institutional investors held Filana Therapeutics (FLNA) as of Q1 2016, down from 49 in Q4 2015.
- Funds reported $57.9M of Filana Therapeutics stock for Q1 2016, up 29% quarter-over-quarter.
- 0 funds opened new Filana Therapeutics positions in Q1 2016 and 5 closed out, a net change of -5 holders.
- The largest Filana Therapeutics buyer in Q1 2016 was Nantahala Capital Management, an estimated $1.15M added.
- The largest Filana Therapeutics seller in Q1 2016 was J. Goldman & Co, an estimated $789K sold.
Based on aggregated 13F filings for Q1 2016.